ANTIBODIES FOR IL-17C
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
1 : An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment cross-competes with an antibody comprising
(a) the HCDR1 region of SEQ ID No.: 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or
(b) the HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No.: 21, the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28.
2 : An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment comprises
(a) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 15, or
(b) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 28.
3 : An antibody or antibody fragment according to claim 2 wherein said antibody or antibody fragment comprises
(a) a HCDR1 region of SEQ ID No.: 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or
(b) a HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No.: 21, the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28.
4 : An antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is specific for human IL-17C.
5 : An isolated antibody or antibody fragment according to claim 4 , wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C.
6 : The antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment.
7 : An antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 17 and a light chain of SEQ ID No.: 16.
8 : An antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 30 and a light chain of SEQ ID No.: 29.
9 : An antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.
10 : An antibody or antibody fragment according to claim 1 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.
11 . (canceled)
12 : A nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding the antibody or antibody fragment according to claim 1 .
13 : A vector composition comprising a vector or a plurality of vectors comprising the nucleic acid sequence or plurality of nucleic acid sequences of claim 12 .
14 : A cell comprising the vector composition of claim 13 .
15 : A pharmaceutical composition comprising the antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier or excipient.
16 : A method for treating a subject with an inflammatory disorder, said method comprising administering the antibody or antibody fragment of claim 1 to the subject.